Kenneth Krogulski - Nov 16, 2023 Form 4/A - Amendment Insider Report for CUMBERLAND PHARMACEUTICALS INC (CPIX)

Role
Director
Signature
Kenneth J. Krogulski by /s/ John Hamm as attorney-in-fact
Stock symbol
CPIX
Transactions as of
Nov 16, 2023
Transactions value $
$3,526
Form type
4/A - Amendment
Date filed
12/6/2023, 05:01 PM
Date Of Original Report
Nov 30, 2023
Previous filing
Nov 17, 2023
Next filing
Dec 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $114 +66 +0.03% $1.73 228K Nov 16, 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $512 +280 +0.12% $1.83 228K Nov 17, 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $456 +268 +0.12% $1.70 228K Nov 20, 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $220 +125 +0.05% $1.76 229K Nov 21, 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $487 +280 +0.12% $1.74 229K Nov 22, 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $705 +379 +0.17% $1.86 229K Nov 27, 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $208 +124 +0.05% $1.68 229K Nov 28, 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $285 +165 +0.07% $1.73 230K Nov 29, 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $538 +324 +0.14% $1.66 230K Nov 30, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May16, 2023.